

1.1.1. GLOBAL INVESTOR STATEMENT

IN SUPPORT OF AN EFFECTIVE, FAIR AND EQUITABLE GLOBAL RESPONSE TO COVID-19

As of 16 April 2021, this statement has already been signed by 158 institutional investors and their representatives with over USD\$ 15 trillion in assets under management or advice. The statement is still open for signature.

As institutional investors with millions of beneficiaries around the world, we recognise and attach considerable importance to the need for an effective, fair and equitable global response to COVID-19. For this reason, we are concerned about the negative impact that limited funding for the [Access to COVID-19 Tools \(ACT\) Accelerator](#) and uneven global access to health technologies (from vaccines and monoclonal antibodies to diagnostics and medical oxygen) will have on the trajectory of the pandemic and global economic activity in the coming years.

A [study](#) commissioned by the International Chamber of Commerce Research Foundation has found that advanced economies that can vaccinate all of their citizens remain at risk of a sluggish recovery with a drag on GDP if infection continues to spread unabated in emerging markets. In fact, the global economy stands to lose as much as US\$ 9.2 trillion if governments fail to ensure that developing economies gain access to COVID-19 vaccines. These losses dwarf the funding needed to enable vaccines to be procured for everyone, everywhere – making a clear “investment case” for full capitalization of the ACT-Accelerator and a coordinated global approach to distribution.

A different [study](#) commissioned by the Bill & Melinda Gates Foundation has reached a similar conclusion: leaving lower-income countries without access to vaccines amid the COVID-19 pandemic will cause significant economic damage that puts decades of economic progress at risk – for both emerging markets and advanced economies alike. The report has estimated that the economic benefits of a global equitable vaccine solution alone for the 10 countries included in the analysis would be at least US\$ 153 billion in 2020-21, rising to US\$ 466 billion by 2025. This is more than 12 times the US\$ 38 billion estimated total cost of the ACT-Accelerator.

Given the pervasive health and social costs of the pandemic, we recognise a strong moral argument to leave no one behind. The two reports above highlight that empowering an effective, fair and equitable global response to COVID-19 via the ACT-Accelerator in 2021 is not only the right thing to do – it also makes full economic sense. We therefore:

- a) Encourage world leaders in the G7, G20 and ACT-Accelerator Facilitation Council to finance the ACT-Accelerator in full and deploy adequate funding to ensure fair and equitable access to COVID-19 tools globally;
- b) Commit to work with the [Access to Medicine Foundation](#) on this issue and engage (bilaterally and/or via existing collaborative initiatives) with our investee healthcare companies to promote industry actions supporting the mission and operations of the ACT-Accelerator (e.g., cross-industry partnerships to accelerate R&D and expand production, equitable pricing strategies, voluntary licensing agreements); and
- c) Recommend that governments and international organisations explore the feasibility of innovative finance mechanisms for national and global COVID-19 responses, similar to [vaccine bonds](#) issued by the International Finance Facility for Immunisation or [social bonds for COVID-19 programmes](#) issued by individual or multiple governments. These mechanisms could build on the strong response by capital markets to ESG-labelled debt issued in 2020.

The International Monetary Fund [has urged](#) the international community to act quickly to make sure that COVID-19 health technologies are available globally to mitigate the risks of virus mutations and address what is currently a deeply inequitable distribution of COVID-19 tools across the world.

We support this call for action. The time to act is now.

SIGNATORY INVESTORS

Listed in alphabetical order by organisation name. Total assets under management in excess of USD\$ 14 trillion.

a.s.r. asset management	Compañía de servicios de bebidas refrescantes pensiones, F.P	Jlens Investor Network
Achmea	Congregation of St. Joseph	Jupiter Asset Management
ACTIAM	Coöperatie VGZ U.A.	KBI Global Investors
Adrian Dominican Sisters, Portfolio Advisory Board	Dana Investment Advisors	Kempen Capital Management
Aegon Asset Management	Daughters of Charity, Province of St. Louise	KLP Kapitalforvaltning AS
Aegon Netherlands	DNB Asset Management	Länsförsäkringar Liv AB
Aequo	Domini Impact Investments LLC	La Banque Postale Asset Management
AkademikerPension	East Capital	La Financière de l'Echiquier
Alecta pensionsförsäkring, ömsesidigt	Ecofi (member of Shareholders for Change)	Liontrust Asset Management PLC
Align Impact	EFG Asset Management	Local Government Super
AllianceBernstein	Egamo	London LGPS CIV Ltd
Alquity Investment Management Limited	EOS at Federated Hermes	M&G Investments
Alternative Bank Schweiz (member of Shareholders for Change)	Ethical Partners Funds Management	Man Group plc
American Century Investments	Ethos (member of Shareholders for Change)	MediRisk
AMP Capital	Etica Funds (member of Shareholders for Change)	Meeschaert Asset Management (member of Shareholders for Change)
ANDA Asset Management Co., Ltd	Everence and the Praxis Mutual Funds	Mercy Investment Services, Inc.
Andbank Wealth Management SGIC	Fair-finance Vorsorgekasse (member of Shareholders for Change)	Midat Cyclops, FP
AP7 (Sjunde AP-fonden)	Fidelity International	Miller/Howard Investments
ASN Beleggingsfondsen	The Folksam Group	Mirova
Asset Management One	Fondazione Finanza Etica (member of Shareholders for Change)	Montanaro Asset Management
Australian Ethical Investment	Fondo de Pensiones de los Empleados de Banco Sabadell GM	Mutualitat dels Enginyers MPS
Avaron Asset Management	Fondo de Pensiones de los Empleados de Banco Sabadell MF2000	NEI Investments
Aviva Investors	Fondo Pensione per il Personale delle Aziende del gruppo Unicredit	Newground Social Investment
Aware Super	Forma Futura (member of Shareholders for Change)	NN Investment Partners
AXA Investment Managers	Forum Equity Partners	Nomura Asset Management
Baloise Asset Management	Friends Provident Foundation (member of Shareholders for Change)	Nordea Asset Management
BancoPosta Fondi Sgr	Fundación Finanzas Eticas (member of Shareholders for Change)	Northwest Coalition for Responsible Investment
Bank für Kirche und Caritas eG (member of Shareholders for Change)	Future Super	OFI Asset Management
BanSabadell Pensiones E.G.F.P., S.A.	GAM Investments	Öhman
BANSABADELL PENTAPENSION EMPRESA FP	Genesis Investment Management	Pædagogernes Pension (PBU)
BBVA Asset Management	GMO	Parnassus Investments
Joh. Berenberg, Gossler & Co. KG (Berenberg)	De Goudse Verzekeringen	Poste Vita S.p.A.
BlueBay Asset Management	Groupama Asset Management	Providence Capital NV
BMO Global Asset Management	HESTA	RAM Active Investments SA
BNP Paribas Asset Management	Hexavest	Rathbone Greenbank Investments
Bon Secours Mercy Health	ICCR	Reynders, McVeigh Capital Management, LLC
Boston Common Asset Management	Impact Investors	Robeco
CANDRIAM	Impax Asset Management Pax World Funds	San Francisco Employees' Retirement System (SFERS)
Castlefield Investment Partners	Indecap Fonder AB	SANSO Investment Solutions (member of Shareholders for Change)
Central Finance Board of the Methodist Church	Insight Investment	Schroders
Church of Sweden	ISGAM AG	SEB Investment Management AB
The Church Pension Fund (Finland)		Shareholders for Change
ClearBridge Investments		The Sisters of St Francis of Philadelphia
Coho Partners		The Socially Responsible Investing Group of 1919 Investment Counsel
Columbia Threadneedle		Statewide Super
Comgest		Stewart Investors
CommonSpirit Health		Stichting Algemeen Pensioenfonds Stap

Stichting Pensioenfonds Huisartsen
Stichting Pensioenfonds Medisch
Specialisten
Storebrand
Sumitomo Mitsui Trust Asset
Management
Sycomore Asset Management
The Maryknoll Sisters
Tokio Marine Asset Management

Trillium Asset Management
Trinetra Investment Management LLP
Trinity Health
Triodos Investment Management
Trusteam Finance
Tundra Fonder
Unipol Group
United Church Funds
The United Church of Canada

USS Investment Management
Vancity Investment Management
Verve Super
VvAA Groep
Wespath Benefits and Investments
WHEB Asset Management
Zevin Asset Management
Zorg En Zekerheid

This investor statement is coordinated by the Access to Medicine Foundation, an independent, non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income countries by stimulating and guiding the pharmaceutical industry to play a greater role in improving access to medicine. It publishes the Access to Medicine Index and the Antimicrobial Resistance Benchmark. The Foundation is funded by the UK Foreign, Commonwealth and Development Office, the Dutch Ministry of Foreign Affairs, the Gates Foundation, the Leona M. and Harry B. Helmsley Charitable Trust, Wellcome Trust and Stewart Investors.

Updated March 2026